What Happened?
San Diego, California-based Turning Point Therapeutics Appointed Ed Gemo as SVP/CIO
Date of management change: February 14, 2021
San Diego, California-based Turning Point Therapeutics Appointed Ed Gemo as SVP/CIO
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Ed Gemo is SVP/CIO at Turning Point Therapeutics. Previously, Ed held various senior IT leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Reeves Mike, Inman Todd, Taylor David, Hayes Sean, Brown Mark, Hoagland Tom, Thompson Mike, Dehne Tanuja, T Cynthia, Ives Royan, Higgins Robert
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.